Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control

COMMENTED

Further Publications

Age effect on treatment responses to 0.05%, 0.025%, and 0.01% atropine: Low-concentration Atropine for Myopia Progression (LAMP) Study

★ 3 Recommended and commented by Dr habil. Gábor Márk Somfai, PhD, Faculty Member

★ 1 Recommended by Prof. Dr emer. Josef Flammer, Faculty Member

Ophthalmology

Li FF, Zhang Y, Zhang X, Kei Yip BH, Tang SM, Kam KW, Young AL, Chen LJ, Tham CC, Pang CP, Yam JC

doi: 10.1016/j.ophtha.2020.12.036

A Randomized, Double-Masked, Placebo-Controlled Clinical Trial of Two Forms of Omega-3 Supplements for Treating Dry Eye Disease

Ophthalmology.

Deinema LA, Vingrys AJ, Wong CY, Jackson DC, Chinnery HR, Downie LE

doi: 10.1016/

RECOMMENDED

Conjunctivitis

A Randomized, Controlled Trial of Cyclosporine A Cationic Emulsion in Pediatric Vernal Keratoconjunctivitis: The VEKTIS Study

Ophthalmology.

Leonardi A, Doan S, Amrane M, Ismail D, Montero J, Németh J, Aragona P, Bremond-Gignac D; VEKTIS Study Group

doi: 10.1016/j.ophtha.2018.

COMMENTED

Retinal Diseases

Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial

★ 2 Recommended and commented by Prof. Dr emer. Josef Flammer, Faculty Member

★ 3 Recommended by Dr Katarzyna Konieczka, Faculty Member

★ 3 Recommended and commented by Dr habil. Gábor Márk Somfai, PhD, Faculty Member

Lancet.

Lotery A, Sivaprasad S, O'Connell A, Harris RA, Culliford L, Ellis L, Cree A, Madhusudhan S, Behar-Cohen F, Chakravarthy U, Peto T, Rogers CA, Reeves BC, VICI trial investigators

doi: 10.1016/S0140-6736(19)32981-2.

RECOMMENDED

Lenses

Effect of High Add Power, Medium Add Power, or Single-Vision Contact Lenses on Myopia Progression in Children: The BLINK Randomized Clinical Trial

★ 2 Recommended by Dr Katarzyna Konieczka, Faculty Member

★ 3 Recommended by Prof. Dr Ke Yao, Faculty Member

JAMA.

Walline JJ, Walker MK, Mutti DO, Jones-Jordan LA, Sinnott LT, Giannoni AG, Bickle KM, Schulle KL, Nixon A, Pierce GE, Berntsen DA, BLINK Study Group

doi: 10.1001/jama.2020.10834.

Cornea and Corneal DiseasesLenses

Ocular and corneal aberrations changes in controlled randomized clinical trial MiSight® Assessment Study Spain (MASS)

BMC Ophthalmol

Lopes-Ferreira D, Ruiz-Pomeda A, Peréz-Sanchéz B, Queirós A, Villa-Collar C

doi: 10.1186/s12886-021-01865-y

Macular Diseases

Pain Control after Intravitreal Injection Using Topical Nepafenac 0.3% or Pressure Patching: A Randomized, Placebo-Controlled Trial

Ophthalmol Retina.

Kaplan RI, Drinkwater OJ, Lee RH, Chod RB, Barash A, Giovinazzo JV, Gologorsky D, Jansen ME, Rosen RB, Gentile RC

doi: 10.1016/j.oret.

Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease

Eur J Ophthalmol.

Nichols KK, Donnenfeld ED, Karpecki PM, Hovanesian JA, Raychaudhuri A, Shojaei A, Zhang S

doi: 10.1177/1120672118791936.

Blindness and Vision Impairment

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial